
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This publication was sponsored by Debiopharm International SA.
This Clinical Brief explores the double-blind, multicentre, randomised phase 2 study (NCT02022098) of Debio 1143 and high-dose cisplatin chemoradiotherapy in patients with high-risk locoregionally advanced squamous cell carcinoma of the head and neck.






